The application for the Pfizer-BioNTech vaccine to be used in children aged six months to four years old has been delayed, the Food and Drug Administration announced Friday.The company submitted the emergency use authorization application on February 1. It included data from the first two doses of the three-dose vaccine set to be used in younger children. A advisory committee panel meeting to discuss the merits of the approval was scheduled for February 15Data for a third shot was supposed to come in later, and the based company planned to apply for authorization for the third shot at another time.
Load More
Load More